Compare DexCom, Inc. (DXCM) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares Core MSCI Emerging Markets ETF — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while iShares Core MSCI Emerging Markets ETF trades at $81.4 (market cap $162.00B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 5.1× DexCom, Inc.'s market cap, and iShares Core MSCI Emerging Markets ETF is more actively traded (13,446,151 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares Core MSCI Emerging Markets ETF for 57 Days on average.
| DXCM | IEMG | |
|---|---|---|
Market Cap | $31.86B | $162.00B |
Volume | 3,607,070 | 13,446,151 |
Sector | Health | Broad Market / Factor |
52-Week High | $92.34 | $86.00 |
52-Week Low | $54.84 | $64.22 |
Typical Hold Time | 62 Days | 57 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
IEMG is trading at $80.5, down 1.88% over the past 24 hours amid a bearish technical signal. The ETF's technical indicators show selling pressure with moving averages signaling bearish momentum, though oscillators remain neutral. Recent news highlights IEMG's strong performance against emerging market peers, with the fund delivering 35% returns over the past year according to Fool - Investing News on 2026-07-06, though it faces higher volatility than broader international alternatives.
The outlook for IEMG remains mixed with technical weakness offset by strong recent performance in emerging markets. Key risks include concentration in technology sectors (39% weighting) and higher volatility compared to developed market ETFs. Analyst comparisons favor IEMG for emerging market exposure but note cost disadvantages versus competitors like SCHE with its 0.03% expense ratio versus IEMG's 0.09%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
